Zacks Investment Research lowered shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) from a buy rating to a hold rating in a research note issued to investors on Friday.

According to Zacks, “Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. “

Several other research firms have also recently issued reports on GLMD. HC Wainwright reaffirmed a buy rating on shares of Galmed Pharmaceuticals in a report on Monday, November 7th. Maxim Group reaffirmed a buy rating and issued a $9.00 price target (down previously from $24.00) on shares of Galmed Pharmaceuticals in a report on Monday, August 1st. Finally, FBR & Co set a $20.00 price target on Galmed Pharmaceuticals and gave the company a buy rating in a report on Friday, August 5th. Five equities research analysts have rated the stock with a buy rating, Galmed Pharmaceuticals presently has an average rating of Buy and an average price target of $12.20.

Galmed Pharmaceuticals (NASDAQ:GLMD) opened at 3.51 on Friday. Galmed Pharmaceuticals has a one year low of $2.78 and a one year high of $9.70. The company has a 50-day moving average price of $3.67 and a 200-day moving average price of $4.16. The firm’s market cap is $42.64 million.

Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.05. Equities analysts predict that Galmed Pharmaceuticals will post ($1.39) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was reported by Daily Political and is the propert of of Daily Political. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be viewed at http://www.dailypolitical.com/2016/12/01/galmed-pharmaceuticals-ltd-glmd-cut-to-hold-at-zacks-investment-research.html.

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. P.A.W. Capital Corp bought a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 60,000 shares of the biopharmaceutical company’s stock, valued at approximately $266,000. P.A.W. Capital Corp owned approximately 0.54% of Galmed Pharmaceuticals at the end of the most recent reporting period. 5.82% of the stock is currently owned by institutional investors.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

5 Day Chart for NASDAQ:GLMD

Get a free copy of the Zacks research report on Galmed Pharmaceuticals (GLMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.